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ABSTRACT
BACKGROUND: Autoimmune diseases complicate pregnancy in several manners. This study aimed at describing the most 
common complications in pregnant women with autoimmune diseases.
METHODS: This was a descriptive and retrospective study. Two groups of pregnant women with autoimmune diseases were 
included: 1) Those who since the beginning of gestation received obstetrical care at a tertiary-level hospital and 2) Women 
who were treated first in a medical unit not specialized in rheumatological diseases. Odds ratio, logistic regression and mul-
tinomial logistic regression were used to determine risk of complicated pregnancy. 
RESULTS: The distribution of autoimmune diseases in our sample is as follows: systemic lupus erythematosus (SLE): 6, rheu-
matoid arthritis (RA): 4, primary anti-phospholipid syndrome (APS): 4, systemic sclerosis (SS): 2, mixed connective tissue 
disease (MCTD): 1. Eight patients were seen throughout their gestation at a tertiary-level hospital and nine were referred 
from other non-specialized hospitals. Patients in the first group had four complications, and those of the second group, 28. 
The Odds Ratio (OR) of having a complication in the hospitals of reference compared to the “Mónica Pretelini Sáenz” Ma-
ternal-Perinatal Hospital (HMPMPS) was of 29.8 (95% CI: 1.29-692.46; Z statistic 2.11, p = 0.03). In relation to the logistic 
regression, this test was not significant neither for the group nor the treatment scheme for the presence of at least one 
complication. The multinomial logistic regression did not show significant predictive probabilities of the different possible 
outcomes for the group and drug treatment scheme.
CONCLUSION: Pregnant women with autoimmune diseases can have an OR up to 29.8 to develop complications when they 
are not cared for by specialized personnel.
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INTRODUCTION
Autoimmune diseases are common in pregnancy [1,2]. Disor-
ders of autoimmunity are classified as follows: a) systemic mul-
tiorganic, in which the antibodies attack antigens that are not 
specific to a particular organ — a clear example of which is Sys-
temic Lupus Erythematosus (SLE) and b) non-systemic, in which 
specific organs are affected. To date, > 80 types of autoimmune 
diseases have been identified that could affect the population, with 
a notable prevalence of 7.6-9.4%, and therefore women with auto-
immune disease may suffer spontaneous abortions and even infer-
tility [3]. An autoimmune crisis can commonly affect blood vessels, 
red blood cells, skin, muscles, and joints, among others [4,5]. All of 
these complications are enhanced during pregnancy [5–7].
When women of reproductive age are affected by autoimmune 
diseases, they suffer more severe consequences; therefore, this 
implies a risk in case of pregnancy due to the possibility of clin-
ical deterioration. One of the diseases of this group that gener-
ates most concern is SLE, as population studies have detected 
complication rates between 2 and 8% in pregnant women, who 
may be more prone to preeclampsia or hypertension, leading to 
maternal-fetal morbidity and mortality. Another example is the 
antiphospholipid syndrome (APS), which can cause such ma-
ternal-fetal complications as preeclampsia, eclampsia, and pla-
cental abruption; additionally, thrombotic manifestations added 
to other obstetric complications can coexist in 2.5–5% of cases 
[8]. Rheumatoid arthritis (RA) affects between 0.5 and 1.0% of 
adults, with a frequency 2–4-times higher in women of repro-
ductive age. It has been shown that the increase of progesterone 
in pregnancy decreases the immune response and consequently 
the level of proinflammatory cytokines, generating remission of 
the disease in a small amount of pregnant women [9].
Hence, patients with autoimmune diseases require extra care 
during pregnancy to avoid the development of complications as-
sociated with these conditions. Therefore, we share a glimpse 
into the major complications of pregnant women with autoim-
mune diseases when they are not treated at specialized hospi-
tals.
METHODS
This was a descriptive and retrospective study. Pregnant women 
seeking care at the “Mónica Pretelini Sáenz” Maternal-Perina-
tal Hospital (HMPMPS), Health Institute of the State of Mexico 
(ISEM), Toluca, Mexico, were included during the period Janu-
ary-December 2012. Two groups of pregnant women with au-
toimmune diseases were established: the first group was seen 
from the beginning of gestation at this tertiary-level hospital, 
and a second group consisted of patients referred from a sec-
ondary-level hospital. We excluded patients with a history of in-
tellectual disability. Those without complete medical files were 
removed from the final analysis.
Sample: The next formula was used to determine the sample to 
be evaluated.
Clinical follow-up: The patient’s demographic data and family his-
tory were obtained from the clinical history in the medical chart, 
and all the information was recorded in an Excel spreadsheet de-
signed for this purpose. Because this was a retrospective and de-
scriptive study, the latter was considered without risk and without 
the need to employ an informed consent form. The protocol was 
approved by the research ethics committee of the HMPMPS and it 
was adhered to the Declaration of Helsinki (Fortaleza, Brazil).
Statistical Analysis: Variables were represented in frequencies. 
Odds ratio (OR) with 95% confidence interval (CI) was calculated for 
the risk of a patient of any group to have a complicated pregnancy. 
For the categorical variable “Presence/Absence” of complication, a 
logistic regression was done for the nominal variables “Group” and 
“Treatment scheme”. The multinomial logistic regression was per-
formed with 12 possible combinations of complications, and five 
registered combinations of antirheumatic treatments. A p-value 
≤ 0.05 was considered statistically significant. All tests were per-
formed with SPSS version 20 (SPPS, Inc., Chicago, IL, USA). 
RESULTS
Seventeen cases of pregnant patients with autoimmune diseases 
were treated, including six with SLE, four with RA, four with prima-
ry APS, two with systemic sclerosis (SS), and one with mixed con-
nective tissue disease (MCTD). Average ages for these were 26.8, 
28.5, 23.5, 26.5, and 22 years, respectively. Of all of the patients, 
eight were cared for throughout their gestation at HMPMPS, and 
nine were referred from other non-specialized hospitals. The for-
mer reached 37.8 weeks of gestation (WG) and the second, 34.1 
WG. The medical management of each patient is shown in Table 1.
Data such as the socioeconomic status of the population group-in-
question were also measured and we found that the study patients 
belonged in 76.4% to the low-income categorization in Mexico (less 
than 461 US$ per month) and 23.5% were referred as medium-in-
come (> 461 and < 2051 US$ per month). According to the gyneco-
logical and obstetrical analyses performed on these patients, five 
patients with SLE were found to be primigravidae and only one was 
multigesta; one patient with RA was primigravida, another patient 
was in her second pregnancy, and only one was multigesta. Among 
patients with APS, one was primigravida, three secundigravidae, 
and one was multigesta. The two patients with SS were primigravi-
dae, and finally, the patient with MCTD was secundigravida.
Of note, 42 family members of the patients seen had one of the 
autoimmune diseases (SLE, RA, SS, or MCTD) and 17 (40.5%) of 
the patients had at least one family member who had the same 
disease (Table 2).
Regarding location of care during pregnancy and its relation to 
outcomes, there were greater number of complications, which 
also were more severe, in those treated in other non-specialized 
hospitals, thus increasing risk at time-of-delivery (Table 3). In ad-
dition, there were two perinatal deaths — these patients were re-
ceiving treatment in non-specialized hospitals at the beginning of 
their gestations. Of the deliveries seen in other hospitals, seven of 
nine infants had a birthweight of < 2,500 g compared to deliveries 
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no = required subjects in each of the samples
Zα = Z alpha corresponding to the 1.645
Zβ = Z beta value corresponding to 1.282
p1 = Value of the proportion of pregnancies without complica-
tions in patients with autoimmune disease receiving a high-lev-
el medical attention = 90%.
p2 = Value of the proportion of pregnancies without complica-
tions in patients with delay in attention by a third level hospital 
= 25%.
p = Mean of the two proportions p1 and p2.
After substituting the values, no = 7.89 patients per group.
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Patient Diagnosis Therapy Annotations
1 Rheumato id 
arthritis
CFT + DCF+ PTTH + PDN
2 Rheumato id 
arthritis
PDN
3 Rheumato id 
arthritis
PDN
4 Rheumato id 
arthritis
AMP + OMP + PDN
5 SLE CFT + DOPA + ENX + FM + HZN + MPS (pulses) + NFP + PD +PDN + TLM
6 SLE CFT + DMP + DXM + ENX + HZN + PDN + TLM
7 SLE AML + CFT + CTC + DOPA + DXM + ENX + FM + HZN + PD + TLM MV (76 h)
8 SLE AML + CFT + DOPA + DXM + FM + HZN + PD + PDN + sHEP MV (42 h)
9 SLE CFT + DXM + ENX + HXC 
10 SLE CFT + PDN + sHEP
11 SLE CFT + NFD + PTP + SCR
12 PSS FT/SLM + RNT + SCR 
13 MCTD AZT + CFT + DXM + ENX + HZN + PDN + TLM Exacerbation in the 
immediate puerpe-
rium
14 AFS Prior to admission to the HMPMPS: DXM + MD + EC (3 U) + PLT for HPTX. 
In the HMPMPS: PA (10 U), AHT (CVD/LST/NFD/PZN/) + ATB (CLM/LFX /
MRP) + ENX + FM + HPD + NTP + SD (MDZ/PPF-DMT) + TFS + TT + CPR (29 
U) + EC (14 U) + FFP (9 U) + rFVII (2 flasks) + PD (103) + EN
MV (312 h) in the 
HMPMPS
15 AFS ASA + CFT + ENX + HZN + PDN + TLM
16 AFS AMP + PDN + TLM
17 AFS AMP + ASA + PDN
Table 1. Medical Management of Patients
AFS: antiphospholipid syndrome, AHT: antihypertensives, AML: amlodipine, AMP: ampicillin, ASA: acetylsalicylic acid, ATB: antibiotics, AZT: 
azathioprine, CFT: ceftriaxone, CLM: clindamycin, CPR: cryoprecipitates, CTC: citicoline, CVD: carvedilol, DCF: diclofenac, DMT: dexmedeto-
midine, DOPA: dopamine, DPM: desmopressin, DXM: dexamethasone (Magann doses), EC: erythrocyte concentrates, EN: enteral nutrition, 
ENX: enoxaparin, FFP: fresh frozen plasma, FM: furosemide, FT/SLM: fluticasone/salmeterol, HMPMPS: “Mónica Pretelini Sáenz” Mater-
nal-Perinatal Hospital, HPTX: hemopneumothorax, HPR: haloperidol, HXC: hydroxychloroquine, HZN: hydralazine IV, LFX: levofloxacin, LST: 
losartan, MCTD: mixed connective tissue disease, MD: methyldopa, MDZ: midazolam, MPS: methylprednisolone, MRP: meropenem, MTC: 
metoclopramide, MV: mechanical ventilation, NFD: nifedipine, NTP: nitroprusside, OMP: omeprazol, PA: platelet apheresis, PD: peritoneal 
dialysis, PDN: prednisone, PLT: pleurotomy, PPF: propofol, PSS: progressive systemic sclerosis, PTP: pantoprazol, PTTH: phototherapy, PZN: 
prazosin, rFVII: Recombinant factor VII, RNT: ranitidine, SC: subclavian catheter, SCR: sucralfate, SD: sedation, sHEP: subcutaneous heparin, 
SLE: systemic lupus erythematosus, TLM: telmisartan, TFS: transfusions, TT: tracheostomy, U: units
Autoimmune disease present in pregnancy








Cancer in family members 1
Familiar thromboembolic disease 1
Family Preeclampsia 3 2
Hypertension 1 1
IURG in the family 4
Other autoimmune diseases in the family 5
Same illness in the family 1 8 4 4
T2DM in the family 6 1
Total 11 9 13 9
Table 2. Hereditary family history in the clinical history in women with autoimmune diseases
APS: primary antiphospholipid syndrome, IUGR: intrauterine growth restriction, RA: rheumatoid arthritis, SLE: systemic lupus erythemato-
sus, SS: systemic sclerosis, T2DM: Type 2 Diabetes mellitus
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ic, another that suffered from bronchospasms, a third one oper-
ated of hemopneumothorax and the last case in chronic dialysis. 
The OR of having a complication in the hospitals of reference com-
pared to the HMPMPS was 29.8 (95% CI: 1.287-692.46, Z statistic 
2.11, p = 0.0342). In relation to the logistic regression, this test was 
not significant for the type of hospital the patient was in or for the 
treatment scheme for the presence of at least one complication. 
The multinomial logistic regression did not show again significant 
predictive probabilities neither for the type of hospital the patient 
was in nor for the drug treatment scheme. Actual status of the 
patients is summarized in Appendix 1.
DISCUSSION
These results demonstrate that there are more complications in 
pregnancies of mothers with autoimmune diseases when they are 
cared for in non-specialized hospitals, with an OR almost reaching 
30, increasing the risks for both mother and baby.
A study by Ngian et al. [10] showed that pregnant women with 
RA usually take a longer time to conceive, are more likely to have 
a Cesarean delivery, and are more likely to have complications 
such as preeclampsia, and in many cases can deliver premature-
ly or have miscarriages, low-birthweight infants and postpartum 
complications. However, patients with a well-controlled RA during 
their pregnancy had favorable outcomes. In this regard, our study 
results were similar in that the majority were primigravidae, all had 
repetitive infections and some had infants with low birthweight. 
In contrast, another case-control study by Postfai et al. [9] found 
that mothers with RA had low socioeconomic status and the most 
frequent complication was iron deficiency anemia; furthermore, 
there was a higher incidence of acute diseases (Influenza-common 
cold and affection of the respiratory, digestive and urinary tract 
systems and in genital organs) compared to healthy mothers. Fi-
nally, Postfai et al. found that a small percentage of infants from 
mothers with RA were low birthweight, which is in agreement with 
our study as we documented that these patients presented more 
acute complications than usual for a normal pregnancy.
A study by Schreiber et al. in women with SLE corroborated that if 
good disease control is maintained in pregnancy, complications can 
be reduced [11]. A more recent study suggests that alteration in 
T-helper cell 17 leads to SLE activation, decreasing regulatory T cell 
levels, leading to increased cytokine and autoantibody prolifera-
tion rates, increasing the disease severity [12]. Obviously, conduct-
ing this type of molecular study, although desirable, lies outside of 
routine practice; thus, clinical evaluation remains the principal tool 
to determine the course of a rheumatic disease in pregnancy.
Available pharmacological alternatives have increased over the last 
decade [13]. This has reduced the risk of teratogenic effects be-
cause, for example, tumor necrosis factor alpha (TNF-α) inhibitors 
are promising for maintaining remission in rheumatologic patients 
and these may be continued for at least the first half of the preg-
nancy [14]. One limitation for implementing this least harmful op-
tion is cost; therefore, more economical drugs are expected to be 
developed. In this respect, preliminary studies have demonstrated 
that phototherapy reduces the expression of TNF-α [15,16], posi-









Acute renal failure 4
Anemia 5










Peptic ulcer disease 1
Polyhydramnios 1 0






Table 3. Acute complications
HMPMPS: “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital, MATHI: 
thrombotic microangiopathy with intravascular hemolysis, MODS: multiple 
organ dysfunction syndrome
at HMPMPS, in which one of eight infants had a birthweight of 
< 2,500 g.
Of the six SLE patients, two (33.3%) had recurrent infections 
(two or more infections during pregnancy), four (66.7%) had 
constitutional manifestations, two (33.3%) had oral ulcers, and 
one (16.66%) had hyperemesis gravidarum (HG). Of the pa-
tients with RA, four (100%) had repetitive infections, one (25%) 
had thromboembolic phenomena, and one (25%) had consti-
tutional manifestations. Of the patients with primary APS, one 
(25%) had recurrent infections, two (50%) had thromboembol-
ic phenomena, and one (25%) had hemorrhagic phenomena. 
Of the patients with SS, one (50%) presented with constitution-
al manifestations, one (50%) was malnourished, and one (50%) 
had Raynaud’s phenomenon. Finally, the patient with MCTD 
had repetitive infections.
According to the established rheumatologic treatment, once 
the women became pregnant, eight patients were treated with 
prednisone alone, two patients were receiving prednisone and 
acetylsalicylic acid, one patient was managed with prednisone 
and diclofenac, and one patient received hydroxyquinoline. 
By their own decision, four patients suspended treatment for 
their autoimmune disease, one woman that was asymptomat-
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diagnosed definite systemic rheumatic disease. 
In summary, we found that pregnant women with autoimmune dis-
eases can have up to seven times more complications when they are 
not seen by skilled personnel. As a result of this observation, it is im-
portant for pregnant women with an autoimmune disease to attend 
specialized hospitals and be cared for by highly trained personnel. 
This can reduce risks and increase the chances of a good outcome 
both in the gestation period and at time-of-delivery. Another more 
realistic solution could be training physicians employed at non-ter-
tiary hospitals to start the most appropriate treatment schemes. 
Along these lines, a possible tool to evaluate skill in the treatment 
of autoimmune diseases during pregnancies could be reduction in 
relative risk (RR) for complications when pregnant women are seen 
by non-specialized institutions. How much should be an acceptable 
RR? This evaluation method could be not restricted to rheumatolog-
ic disease only but could be used for any disease. 
The narrower the margin of difference between a specialized hospi-
tal or one of the second level of care, the more qualified the health 
system as a whole will be to treat this type of pathology.
tioning it as an alternative in women with autoimmune diseas-
es, yet to our knowledge no guidelines have been established 
for this potential treatment. 
Given the results of the logistic and multinomial regressions, 
it appears that the better outcome in the patients who were 
managed in a specialized hospital was not due to a better 
pharmacological scheme, on the contrary,  it is likely that the 
availability of a multitude of resources, including multispecial-
ty attention and laboratories, result in better outcomes.
A limitation of this study is the low number of cases, but the 
findings of this study are still valuable as publications on rheu-
matological diseases in pregnancy are not as numerous as 
expected. For example, Galapatthy et al. [17], described that 
from a full population cohort of 72 women with SLE three be-
came pregnant and underwent successful pregnancies. In a 
screening performed by Spinillo et al. [18] in 2,458 pregnant 
women in their first trimester, the authors identified 62 (2.5%) 
women with previously undiagnosed undifferentiated connec-
tive tissue disease and 24 (0.98%) women with previously un-
9. É. Pósfai, F. Bánhidy, R. Urbán, A. E. Czeizel, “Birth Outcomes of 
Children Born to Women with Rheumatoid Arthritis”, Cent Eur J Pub-
lic Health, vol. 23, no. 2, pp. 104–110, 2015. doi: 10.21101/cejph.
a3968 
10. G. S. Ngian, A. M. Briggs, I. N. Ackerman, S. Van Doornum, “Man-
agement of pregnancy in women with rheumatoid arthritis”, Med J 
Aust, vol. 204, no. 2, pp. 62–63, 2016. 
11. K. Schreiber, “Pregnancies in women with systemic lupus erythe-
matosus and antiphospholipid antibodies”, Lupus, vol. 25, no. 4, pp. 
343–345, 2016. doi: 10.1177/0961203315627201.
12. A. S. Figueiredo, A. Schumacher, “The T helper type 17/regula-
tory T cell paradigm in pregnancy”, Immunology, vol. 148, no. 1, pp. 
13–21, 2016. doi: 10.1111/imm.12595. 
13. C. Baldwin, A. Avina-Zubieta, S. K. Rai, E. Carruthers, M. A. De 
Vera, “Disease-modifying anti-rheumatic drug use in pregnant wom-
en with rheumatic diseases: a systematic review of the risk of con-
genital malformations”, Clin Exp Rheumatol, vol. 34, no. 2, 172-183. 
2016.
14. M. Østensen, L. Andreoli, A. Brucato, I. Cetin, C. Chambers, M. 
E. Clowse, et al., “State of the art: Reproduction and pregnancy in 
rheumatic diseases”, Autoimmun Rev, vol. 14, no. 5, pp. 376-386. 
2015. doi: 10.1016/j.autrev.2014.12.011. 
15. J. Meneses Calderón, I. González Sánchez, G. Aburto Huacuz, A. 
S. Alonso Barreto, M. C. Colín Ferreyra, H. Mendieta Zerón, “Trends 
of inflammatory markers and cytokines after one month of photo-
therapy in patients with rheumatoid arthritis”, Acta Medica Acad, 
vol. 44, no. 2, pp. 102–108, 2015. doi: 10.5644/ama2006-124.137.
16. J. Meneses Calderón, G. Aburto Huacuz, I. González Sánchez, A. 
Gutiérrez Vilchis, H. Mendieta Zerón. “Phototherapy Induces an Im-
provement In Clinical and Biochemical Scores In Rheumatoid Arthri-
tis”, West Indian Med J, vol. 65, 2016. doi: 10.7727/wimj.2015.490. 
17. P. Galapatthy, A. N. Wazeel, S. Nanayakkara, R. Sheriff, “Clinical 
features of systemic lupus erythematosus in Sri Lankan patients: re-
sults from a lupus clinic”, Ceylon Med J, vol. 45, no. 4, pp. 162-165, 
2000.
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Patient Diagnosis Evolution
1 R h e u m a t o i d 
arthritis
After delivery (cesarea) she was treated with PDN, MTX and PTTH, the RAQoL test decreased 
from 56 in immediate puerperium to 17 after four years. Last medical visit was on September 
2017 when she moved to the north of Mexico.
2 R h e u m a t o i d 
arthritis
Her baby was born by vaginal delivery. She missed several medical appointments. She was 
treated with DMARDs. She was programmed for puncture-aspiration and steroid application for 
hemarthrosis in the left knee but she no longer returned after June 2015.
3 R h e u m a t o i d 
arthritis
After delivery (cesarea) she received MTX, SSZ and PDN for seven months and she did not re-
turn. Last medical visit on May 2012.
4 R h e u m a t o i d 
arthritis
After pregnancy interruption through vaginal delivery she had a 41 joints with pain and a RAQoL 
of 30. She was prescribed a treatment with HXC, MTX, PDN and PTTH. The symptomatology had 
a remission after seven weeks and she is actually on treatment with only MTX. Las medical visit 
on June 2019.
5 SLE Pregnancy attended by caesarean section and after two months she was referred to her medical 
service. Last medical consultation on 2011. 
6 SLE Pregnancy attended by caesarean section and was treated with PDN and dipyridamole. Last 
medical visit on 2010.
7 SLE She have had repeated upper respiratory infections and depression. Las medical visit on May 
2019.
8 SLE She was programmed for renal biopsy but she did not return. Last medical visit on 2010. 
9 SLE She was kept on treatment based on PDN until March 2010 when she moved to USA.
10 SLE The maintenance treatment was based on PDN, statins and fibrates but PDN was suspended 
when she was diagnosed with depression and was changed to HXC.
11 SLE Pregnancy attended by caesarean section and almost immediately she changed of medical 
health insurance system.
12 PSS First pregnancy attended by cesarean on July 2011. She only came back for two medical con-
sultations and did not return until the year 2016 with a second pregnancy attended again by 
cesarean section on August 2016 and did not come back until a third pregnancy on 2018 leading 
to a third cesarea. Last medical visit on January 2019.
13 MCTD Pregnancy attended by caesarean section. She experienced clinical deterioration despite treat-
ment with AZT, MTX and high doses of PDN, so was referred to a National Institute of Health on 
December 2011.
14 AFS She required cesarean surgery plus hysterectomy. Maintenance treatment was with ASA and 
dipyridamole and was referred to her local General Hospital in the year 2010.
15 AFS She was submitted to cesarean surgery and chronic treatment was established with warfarin 
and after two months of follow-up she moved to another Mexican State (year 2009).
16 AFS She was submitted to vaginal delivery but the baby died in utero. She was receiving multidis-
ciplinary treatment to be in good health condition for another pregnancy but she moved to 
another Mexican State (year 2010).
17 AFS Pregnancy attended by caesarean section. After the third medical consultation she did not re-
turn to the Hospital (year 2010).
18. A. Spinillo, F. Beneventi, V. Ramoni, R. Caporali, E. Locatel-
li, M. Simonetta, et al., “Prevalence and significance of pre-
viously undiagnosed rheumatic diseases in pregnancy”, Ann Rheum 
Dis, vol. 71, no. 6, pp. 918-923, 2012. doi: 10.1136/annrheum-
dis-2011-154146. 
Appendix 1. Actual status of the patients
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